March 27, 2023

Dear Chairwoman Granger, Ranking Member DeLauro, Chairman Diaz Balart, Ranking Member Lee, Senator Murray, Senator Collins, Senator Coons and Senator Graham:

As private sector corporations and organizations, we come together to urge you as leaders in Congress to support a sustained, robust contribution to the Global Fund to Fight AIDS, Tuberculosis and Malaria in fiscal year 2024.

The U.S.-hosted Global Fund replenishment conference last fall in New York broke records for the total pledges to AIDS, TB and malaria programs, spurred by the U.S. pledge. Thank you for the strong funding you included in the fiscal year 2023 omnibus appropriation.

We ask you to maintain robust funding to protect hard-won gains against HIV/AIDS, TB and malaria, to help countries prevent future health emergencies, to achieve demonstrable economic benefits and to continue U.S. leadership in global health.

**Impact:** The Global Fund’s impact is undeniable. The Global Fund and its partners have saved more than 50 million lives since its founding in 2002—reducing the combined death toll from HIV/AIDS, TB and malaria by more than half in countries where it invests. In 2021, the Global Fund partnership provided antiretroviral treatment for 23.3 million people with HIV, treated 5.3 million people for TB and funded the distribution of over 133 million bed nets for malaria prevention.

**Surmounting challenges:** The internationally agreed goal of ending AIDS, TB and malaria as epidemics faces several challenges. Women and girls remain particularly vulnerable to the diseases. Other key populations face stigma and lack of access to care. The growing youth population in Africa and elsewhere means that responses must accelerate. Multidrug resistance to therapies and resistance to malaria bed net insecticides must be overcome.

Amid disruptions from COVID-19, progress against HIV/AIDS, TB and malaria temporarily lost ground. However, U.S. investments in the Global Fund helped protect these critical programs and get back on
track toward a future free of the three epidemics. Long-term and COVID-era Global Fund investments in resilient health systems are also helping countries be ready for future health challenges.

**Comparative competencies:** The Global Fund makes health commodities available to implementing countries’ populations by utilizing large-scale pooled procurement, bolstering supply chains and speeding innovations to deployment. It strengthens health systems and invests in local health workers to address HIV/AIDS, TB and malaria and be better prepared for future pandemic threats. The Global Fund has deep relationships with governments, community caregivers and affected populations in over 120 countries. It prioritizes accountability through robust impact metrics, an independent Inspector General and whistleblower protection.

**Benefits to Americans:** Sustaining investment in the Global Fund serves America, its economy, its trade and diplomatic goals, and its people. Every dollar invested in the Global Fund yields $31 in economic benefits. The Global Fund and U.S. bilateral global health programs collaborate closely and depend on each other for success.

**Rallying others:** U.S. law caps U.S. support for the Global Fund at 33% of its total budget, leveraging funding from other donors. At last fall’s Global Fund replenishment conference, the bold U.S. pledge encouraged several major donors — including Canada, Japan, Germany, France and the European Commission -- to markedly increase their own pledges.

In addition to support for the Global Fund, we also urge swift reauthorization of the President’s Emergency Plan for AIDS Relief (PEPFAR), which works hand in hand with the Global Fund to amplify lifesaving impact.

Thank you for your stewardship of taxpayer resources, and for placing a priority on the Global Fund as a tested and proven investment that offers unparalleled returns in health and economic security.

Sincerely,

Cepheid
Chevron
The Coca-Cola Company
Dimagi
Freight In Time
Gilead Sciences
Hetero Drugs Ltd.
Johnson & Johnson
MACRO-EYES
(RED)

Roche
S.C. Johnson & Son
Thermo Fisher Scientific
Transamerica
Vestergaard
Viatris
ViiV Healthcare
Zenysis Technologies